Ann: NTCELL Parkinsons trial 2 year data analysis shows success, page-60

@jeffries 2 continuing on from your point on the graphical data comparing this graph versus that released at 18 months .

What is the dotted line now at -7 - surely baseline ( if that is what it is) surely should start at zero. First time this line has appeared below zero . It did on the 18 month chart. no highs and lows shown on this chart / it was displayed at 18 months. I misread the graph because I thought that dotted line was baseline - as I read it now still the placebo patients on average 2 years on have not deteriorated on this scale versus their start point ? I must be misreading . ?
120 cohort removed ( understandably) but therefore where or when will the 2.5 year data for 40/80 cohorts be ready - should be ready now. If you accept that 120 didn't work surely the deterioration in those patients is relevant particularly as the placebo patients do not seem to have deteriorated. The 120 dosage would not have accelerated the progression of the disease. So these 120 patients could almost add to the placebo stats

Seeing as they spent 2 months pouring over the data at least they could label all the lines. I am amazed at the crudity of the data as presented to be honest .

Appreciate anyone with a better understanding qualifying the graph for me.